Developing imaging agents for specific types of tau-related brain diseases

In Vitro and In Vivo Characterization of PET Radiotracers for the 4R Variant of Tau

NIH-funded research University of Pennsylvania · NIH-10940635

This study is working on a new imaging tool that helps doctors spot certain brain diseases, like progressive supranuclear palsy and corticobasal degeneration, more accurately, so patients can get better diagnoses and treatments that are just right for them.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Pennsylvania NIH-funded
Lab location1 site (Philadelphia, United States)
Project IDNIH-10940635 on NIH RePORTER

What this research studies

This research focuses on creating a new type of imaging agent called a PET radiopharmaceutical that can specifically identify 4-repeat tauopathies, which are brain diseases like progressive supranuclear palsy and corticobasal degeneration. By improving the sensitivity and specificity of these imaging agents, the research aims to better differentiate between various tau-related conditions and assess the effectiveness of new treatments targeting tau. Patients will benefit from enhanced diagnostic capabilities that could lead to more tailored and effective therapies. The research involves both laboratory studies and testing in animal models to evaluate the performance of these new agents.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with 4-repeat tauopathies such as progressive supranuclear palsy, corticobasal degeneration, or frontotemporal lobar degeneration.

Not a fit: Patients with other types of dementia or neurological conditions unrelated to tauopathies may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved diagnostic tools and treatment options for patients with tauopathies.

How similar studies have performed: Previous research has shown promise in developing PET agents for imaging tau aggregates, but this specific focus on 4-repeat tauopathies is relatively novel.

Where this research is happening

Philadelphia, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's DiseaseAlzheimer's disease therapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.